CryoLife to start human trials of its BioGlue
This article was originally published in Clinica
The FDA has told CryoLife that it can begin human trials of its BioGlue surgical adhesive for repairing aortic dissections. The Atlanta, Georgia-based company claims the product is the first in the US to be used in aortic dissections.
You may also be interested in...
Target guests in selected locations will be able to shop a curated Ulta Beauty section in the second half of 2021. The partnership could attract new clientele to Target stores and give Ulta a boost following nationwide store closures this year due to COVID.
COVID-19 Vaccines: ACIP’s Allocation Proposal Prioritizes Long-Term Care Residents, Essential Workers
First group to receive vaccine would comprise health care personnel and residents of long-term care facilities; next in line are non-health care essential workers, who would take priority over adults with high-risk medical conditions and those ages 65 years and older, according to the CDC advisory committee’s proposed allocation framework.
Azar says ACIP’s prioritization recommendations should carry weight, but states will be final arbiter of who is vaccinated.